Explore the words cloud of the PREFER project. It provides you a very rough idea of what is the project "PREFER" about.
The following table provides information about the project.
Coordinator |
UPPSALA UNIVERSITET
Organization address contact info |
Coordinator Country | Sweden [SE] |
Project website | http://www.imi-prefer.eu |
Total cost | 12˙000˙001 € |
EC max contribution | 6˙000˙000 € (50%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2015-05-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2016 |
Duration (year-month-day) | from 2016-10-01 to 2021-09-30 |
Take a look of project's partnership.
The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on withdrawal of drugs from the market. A broad array of (combinations of) patient preference methods will be tested prospectively in a large number of case studies. The availability of large patient cohorts will enable to test new methods or deviations from existing methods in a randomized manner, by comparing well-known methods with newer ones. The use of simulation studies will both contribute to smarter design of case studies and to exploring the sensitivity of outcomes of preference studies. Based on discussions with a broad representation of stakeholders e.g. patients, patient organisations, regulatory authorities, HTA bodies and reimbursement agencies, suitable methods will be tested and their contributions to improved decision making will be discussed in recommendations adapted to the needs of all relevant stakeholders. The recommendations from PREFER are expected to lead to changed practices, in that industry will routinely assess whether a preference study would add value at key decision points in the medicinal product life cycle and, if so, implement patient-preference elicitation studies according to the PREFER project recommendations. The PREFER consortium consist of 16 industry partners and 16 academic and SME members including representation from academia, patient organizations, HTA bodies, reimbursement agencies, and project management.
Report characterising the types and possible role of psychological instruments and educational tools in measuring patient preferences | Documents, reports | 2020-04-08 21:05:17 |
Report characterising the criteria to be used to assess the performance of patient-preference methods, the performance of the methods on these criteria, and a gap analysis | Documents, reports | 2020-04-08 21:05:17 |
Final scope document for recommendations | Documents, reports | 2020-04-08 21:05:18 |
Dissemination and communication plan | Documents, reports | 2020-04-08 21:05:18 |
Report describing the candidate methodologies and assessment criteria to go forward for testing in empirical case studies and simulation studies | Documents, reports | 2020-04-08 21:05:18 |
Initial data management plan | Documents, reports | 2020-04-08 21:05:18 |
Report characterising the desires, expectations concerns, and requirements of stakeholders about methodologies for patient-preference elicitation | Documents, reports | 2020-04-08 21:05:17 |
Open workshop on preference elicitation | Websites, patent fillings, videos etc. | 2020-04-08 21:05:18 |
Report describing existing processes, conditions, and contextual factors that influence the utility and role of patientpreference studies and the rationale behind such influence | Documents, reports | 2020-04-08 21:05:17 |
Report characterising the decision points throughout the medicinal product life cycle, the activities that are carried out in each step, and the types of assessments made at these points, as well as the assessment criteria used by different stakeholders | Documents, reports | 2020-04-08 21:05:17 |
Website launch | Websites, patent fillings, videos etc. | 2020-04-08 21:05:18 |
Report describing existing qualitative and quantitative methods for measuring patient benefit-risk preferences in medical treatment | Documents, reports | 2020-04-08 21:05:17 |
Report describing the requirements for patient-preference elicitation case studies to inform benefit-risk decision making for industry, Regulatory Authorities, HTA bodies, and reimbursement agencies at different decision points | Documents, reports | 2020-04-08 21:05:18 |
Defining Key Performance Indicators (KPIs) | Documents, reports | 2020-04-08 21:05:18 |
Final report on operational requirements for the conduct of case studies | Documents, reports | 2020-02-17 17:32:43 |
Take a look to the deliverables list in detail: detailed list of PREFER deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2019 |
Rosanne Janssens, Selena Russo, Eline van Overbeeke, Chiara Whichello, Sarah Harding, Jürgen Kübler, Juhaeri Juhaeri, Karin Schölin Bywall, Alina Comanescu, Axel Hueber, Matthias Englbrecht, Nikoletta Nikolenko, Gabriella Pravettoni, Steven Simoens, Hilde Stevens, Richard Hermann, Bennett Levitan, Irina Cleemput, Esther de Bekker-Grob, Jorien Veldwijk, Isabelle Huys Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA published pages: 513-526, ISSN: 1178-1653, DOI: 10.1007/s40271-019-00367-w |
The Patient - Patient-Centered Outcomes Research 12/5 | 2020-04-08 |
2019 |
Vikas Soekhai, Chiara Whichello, Bennett Levitan, Jorien Veldwijk, Cathy Anne Pinto, Bas Donkers, Isabelle Huys, Eline van Overbeeke, Juhaeri Juhaeri, Esther W. de Bekker-Grob Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review published pages: 1324-1331, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.05.001 |
Drug Discovery Today 24/7 | 2020-04-08 |
2019 |
Rosanne Janssens, Isabelle Huys, Eline van Overbeeke, Chiara Whichello, Sarah Harding, Jürgen Kübler, Juhaeri Juhaeri, Antonio Ciaglia, Steven Simoens, Hilde Stevens, Meredith Smith, Bennett Levitan, Irina Cleemput, Esther de Bekker-Grob, Jorien Veldwijk Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review published pages: , ISSN: 1472-6947, DOI: 10.1186/s12911-019-0875-z |
BMC Medical Informatics and Decision Making 19/1 | 2020-04-08 |
2019 |
Selena Russo, Chiara Jongerius, Flavia Faccio, Silvia F.M. Pizzoli, Cathy Anne Pinto, Jorien Veldwijk, Rosanne Janssens, Gwenda Simons, Marie Falahee, Esther de Bekker-Grob, Isabelle Huys, Douwe Postmus, Ulrik Kihlbom, Gabriella Pravettoni Understanding Patients\' Preferences: A Systematic Review of Psychological Instruments Used in Patients\' Preference and Decision Studies published pages: 491-501, ISSN: 1098-3015, DOI: 10.1016/j.jval.2018.12.007 |
Value in Health 22/4 | 2020-04-08 |
2019 |
Chiara Whichello, Eline van Overbeeke, Rosanne Janssens, Karin Schölin Bywall, Selena Russo, Jorien Veldwijk, Irina Cleemput, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Meredith Smith, Richard Hermann, Matthias Englbrecht, Axel J. Hueber, Alina Comanescu, Sarah Harding, Steven Simoens, Isabelle Huys, Esther W. de Bekker-Grob Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US published pages: , ISSN: 1663-9812, DOI: 10.3389/fphar.2019.01009 |
Frontiers in Pharmacology 10 | 2020-04-08 |
2017 |
Esther W. de Bekker-Grob, Conny Berlin, Bennett Levitan, Karim Raza, Kalliopi Christoforidi, Irina Cleemput, Jana Pelouchova, Harald Enzmann, Nigel Cook, Mats G. Hansson Giving Patients’ Preferences a Voice in Medical Treatment Life Cycle: The PREFER Public–Private Project published pages: 263-266, ISSN: 1178-1653, DOI: 10.1007/s40271-017-0222-3 |
The Patient - Patient-Centered Outcomes Research 10/3 | 2020-04-08 |
2018 |
Eline van Overbeeke, Chiara Whichello, Rosanne Janssens, Jorien Veldwijk, Irina Cleemput, Steven Simoens, Juhaeri Juhaeri, Bennett Levitan, Jürgen Kübler, Esther de Bekker-Grob, Isabelle Huys Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review published pages: , ISSN: 1359-6446, DOI: 10.1016/j.drudis.2018.09.015 |
Drug Discovery Today | 2020-04-08 |
2018 |
de Bekker-Grob, Esther W.; Juhaeri, Juhaeri; Kihlbom, Ulrik; Levitan, Bennett et al. Giving patients\' preferences a voice in the medical product lifecycle: w018y, when and how?: The public-private PREFER project: Work package 2 published pages: p. 19-21, ISSN: 2375-866X, DOI: |
ISPOR Value & Outcomes Spotlight Vol. 4, no 3 | 2020-04-08 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREFER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PREFER" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More